Eczema (Atopic Dermatitis) Insurance Denial: How to Appeal

Atopic dermatitis (eczema) can be relentless — cracked, weeping skin, constant itch, and sleepless nights. For moderate-to-severe cases, newer treatments like Dupixent (dupilumab), Rinvoq (upadacitinib), and Cibinqo (abrocitinib) offer genuine relief. But insurance companies routinely deny these medications, forcing patients to fight for access. If you've received a denial, this guide explains exactly how to appeal.

Why Insurers Deny Atopic Dermatitis Treatments

Dupixent step therapy: Insurers almost universally require failure on topical corticosteroids (TCS), topical calcineurin inhibitors (TCIs) like tacrolimus and pimecrolimus, and sometimes wet wrap therapy before approving Dupixent.

JAK inhibitor restrictions: Rinvoq and Cibinqo face additional scrutiny because of their black box warning (serious infections, cancer risk, cardiovascular events). Insurers may require Dupixent failure before approving a JAK inhibitor.

Newer biologics: Adbry (tralokinumab) and Ebglyss (lebrikizumab) face "lack of medical necessity" denials because reviewers may be unfamiliar with the clinical data.

Inadequate severity documentation: Without objective severity scores, denials frequently cite insufficient evidence of moderate-to-severe disease.

Severity Scoring: Document Everything

Three scoring tools are standard for atopic dermatitis:

EASI (Eczema Area and Severity Index): Scores range 0–72. Scores above 21 represent severe disease. Scores of 7–21 are moderate. EASI is the most widely used tool in clinical trials and insurance appeals.

SCORAD (Scoring Atopic Dermatitis): Combines objective signs (area, intensity) and subjective symptoms (itch, sleep loss). A score above 50 is severe; 25–50 is moderate. The sleep component is particularly important for documenting quality-of-life impact.

IGA (Investigator Global Assessment): A 5-point scale (0 = clear, 4 = severe). An IGA of 3 (moderate) or 4 (severe) is the standard threshold for biologic approval.

Request that your dermatologist formally document all three at each visit and include them in any Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization submission.

Documenting Topical Therapy Failures

For Dupixent approval, you typically need to document failure on:

1. Topical corticosteroids (TCS): At least two trials of medium-to-high potency steroids (e.g., triamcinolone 0.1%, fluocinonide). Document duration (usually 4–8 weeks), percentage BSA applied, and reason for inadequate response or side effects (skin atrophy, striae, HPA axis suppression with prolonged use).

Note contraindications where applicable — patients with extensive BSA involvement may not achieve sufficient control with topicals even when used correctly, which itself justifies biologic escalation.

Addressing JAK Inhibitor Black Box Warnings in Your Appeal

If your dermatologist recommends Rinvoq or Cibinqo after Dupixent failure, expect heightened scrutiny. Your appeal should:

• Document the specific reason Dupixent was inadequate (partial response, injection site reactions, ocular side effects like conjunctivitis)
• Reference the FDA-approved indication for upadacitinib and abrocitinib specifically for moderate-to-severe AD in patients 12+ years
• Note that prescribing dermatologist has evaluated cardiovascular and malignancy risk factors and determined benefit outweighs risk
• Cite FAAD (Fellow of the American Academy of Dermatology) guidelines on JAK inhibitor use in AD

FAAD Guidelines as Appeal Evidence

The American Academy of Dermatology (AAD) guidelines on atopic dermatitis biologics and systemic therapy are authoritative sources for appeal letters:

• AAD Clinical Practice Guidelines for Atopic Dermatitis (2023 update)
• Position statements on access to biologic therapy
• Guidance on sequencing: topicals → dupilumab → JAK inhibitors in appropriate candidates

Your appeal letter should quote relevant sections directly and include your dermatologist's attestation that care is consistent with AAD guidelines.

Peer-to-Peer Review and Expedited Appeals

If your initial appeal is denied, push for a peer-to-peer review — a phone call between your dermatologist and the insurance company's medical director. Dermatologists who are board-certified and FAAD-designated often find reviewers will approve cases that were denied on paper.

For patients with severe disease causing sleep loss, impaired ability to work, or secondary infections requiring hospitalization, request an expedited appeal (decision within 72 hours) and document the urgent clinical basis.

Fight Back With ClaimBack

ClaimBack generates complete atopic dermatitis appeal letters with EASI/SCORAD/IGA frameworks, step therapy documentation, and AAD/FAAD guideline citations.

Start your free appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal